UFT/Methotrexate/Leucovorin for Breast Cancer Patients in Progression After HDCT/PBPC Support
ByMiguel Martin, MD, PhD,Antonio Casado, MD,José Antonio López-Martin, MD,Alvaro Rodriguez-lescure, MD,Yago Nieto, MD,Francisco Ayala, MD,Eduardo Diaz-rubio, MD, PhD
Published: | Updated:
Twenty-four patients with metastatic breast cancer that had progressed after high-dose chemotherapy with peripheral blood progenitor cell (PBPC) support were given intramuscular methotrexate in combination with oral